Antimicrobial Resistance: The Difference We Make Together

On the 26th of September 2018, Becton Dickinson (BD), in collaboration with University Medical Center (UMC) Utrecht, is organizing an antimicrobial resistance international symposium in Utrecht, The Netherlands.

The program features international speakers who will cover topics such as the impact of AMR on patients, antimicrobial drug discovery, emergence and spread of antibiotic resistant bacteria, and so on. Prof. Dr. Marc Bonten – Scientific Coordinator of the COMBACTE project – is also one of the confirmed speakers during the event.

Registration can be done via this page. Registration fee is €25.

Vincent A. Forlenza – BD Chairman of the Board, Chief Executive Officer and President: “The rapid growth of antimicrobial resistance (AMR) transcends its devastating impact on human health. AMR is emerging among the world’s leading global security and economic threats, demanding the attention of world leaders. Based on current trends, AMR will cause an estimated 10 million deaths annually by 2050, surpassing the number of deaths caused by cancer.

BD joins with industry and world leaders in calling for mobilization of a global, collaborative alliance to address the threat of AMR. We stand ready to support this vital effort with 120 years of expertise in advancing medical practice and an extensive portfolio of products and solutions that facilitate infection prevention and control, diagnosis, surveillance and reporting, including infections resistant to antimicrobial treatment. We also bring decades of firsthand experience collaborating across the public and private sectors to advance global health in areas such as childhood immunization, HIV & AIDS, tuberculosis, sepsis and healthcare-associated infections.

The threat of AMR requires full engagement and partnership among all stakeholders, including patients, clinicians, government and nongovernment agencies, academic institutions and companies. Together, we must be the first and final line of defense.”